

Curriculum vitae

Personal information

ALESSANDRA ROMANO, M.D., Ph.D.

VIA CONVENTO DEL CARMINE 10 PAL.L- TREMESTIERI ETNEO (CATANIA)- ITALY

+39 3273971491

Date of birth 15/01/1983

Nationality: Italian, passport number: AA2678136

EDUCATION AND TRAINING

May 2018 Selected Fellow at III International School on Emergency Accounting

July 2017: European Hematology Exam passed, certified by EHA (European Hematology Association)

09/07/2016: Specialization in Hematology, 70/70 cum laude

03/02/2012 Grant Writing Certification (Expert Level), score 100%

01/26/2011 Ph.D., XXIII International PhD course of SSC- University of Catania in Stem Cells and molecular medicine, 70/70 cum laude, thesis title: High resolution molecular karyotyping and proteomic analysis in hematological malignancies, endorsing professors: Lance Liotta and Francesco Di Raimondo.

5th-19th July 2008 International School of Functional Genomics, director S. Cavallaro

4th-11st July 2008 Translational medicine course, director L. Liotta, grade A

January 2008 Board certification

01/31/2008 SSC-Scuola Superiore di Catania degree, 70/70 marks and laudem. Thesis title: "Salvage therapy with vinorelbine, ifosfamide and cytarabine regimen (VIHA) in Non-Hodgkin lymphomas."

August 2006 - October 2007: Training in Haematologic Unit of Istituto Clinico Humanitas, endorsing professor: A. Santoro, working about salvage chemotherapy in lymphoma and transplantation.

07/25/2007 Medicine degree. 110/110 marks and laudem. Thesis title: "Salvage therapy with intravenous bortezomib, melphalan and dexamethasone in previously treated myeloma patients."

From October 2005 Training in Haematologic Clinical Division of Hospital Ferrarotto of Catania, supervisor: prof. Francesco Di Raimondo.

January- July 2005 Team leader in the 8th Student ESA parabolic flight campaign, to test cell survival in microgravity (first 25 selected in Europe and Canada)

June-December 2004 Training in Biochemical Lab of University of Catania, directed by Prof. D. Condorelli, working about Pol-A gene expression

From September 2001: effective student in SSC-Scuola Superiore di Catania.

June 2001 High School Graduation at Liceo Scientifico G. Galilei, Catania, 100/100 marks

WORK AND RESEARCH EXPERIENCES

January-March 2019 Post-doc fellow at Ca' Foscari University, Department of nanoscience

January-December 2018: Research Assistant at University of Catania, CHIRMED, Department of Medical sciences and surgical specialties, Hematology Section

From June 2017-now: Research Assistant ("*Cultore della Materia*") in Blood Diseases (MED/15) at University of Catania

September 2016-December 2017 Post-doc fellow at Ospedale San Raffaele, Age Related Diseases Unit, Milano, Italy

April-July 2016: visiting scientist at Ospedale San Raffaele, Age Related Diseases Unit, Milano, Italy endorsed by dr. S. Cenci

October 2013-May 2014: Post Doc Fellow at Johns Hopkins University- School of Medicine, Department of Oncology, endorsing prof. Ivan Borrello

June 2015-April 2017 co-investigator in research program (Non-clinical Research Grant Recipient-ITA-051) funded by Celgene *Exploiting Ikaros and Aiolos in controlling MDSC expansion in Multiple Myeloma*

From January 2014 sub-investigator in the national grant from Health Minister (ricerca finalizzata) in collaboration with Johns Hopkins University to detect MDSC in Multiple Myeloma (P.I. Francesco Di Raimondo and Ivan Borrello)

January 2013-December 2016 sub-investigator in the national grant PON 2010-2012 Hippocrates to detect Arginase using innovative nanotechnology (P.I. F. Di Raimondo)

From 11/01/2010 to 01/31/2011 Senior researcher at George Mason University, Manassas, VA, in charge of ISS, Istituto Superiore di Sanita, Rome, Italy for *detection of biomarkers in high-risk Myelodysplastic Syndromes*

From 08/02/2009 to 10/31/2010 Research Assistant at George Mason University, Manassas, VA, working on translational research: *Ex vivo assay for targeted therapy in Multiple Myeloma*

GRANTS

November 2016, 2017 Brian D. Novis Junior Research Award (1-yr, 50,000 dollars, PI)

June 2015-April 2017 Non-clinical Research Grant Recipient-ITA-051 funded by Celgene *Exploiting Ikaros and Aiolos in controlling MDSC expansion in Multiple Myeloma*

February 2014, RF-2010-2318830, granted by Health Minister (Ricerca Finalizzata 2011-2012)

From December 2012 to September 2014 RG ITA-003 - PO 3517441 funded by Celgene (Non-clinical Research Grant Recipient, 2-yrs, 30,000 euro): *Evaluation of pro-survival pathways, included autophagy, in high-risk MDS bone marrow after treatment with 5-azacitidine to restore normal hematopoiesis*

From August 2010 to October 2011 M-190 funded by Celgene (Non-clinical Research Grant Recipient, 20,000 euro, 2-yrs-sub-investigator): *Molecular karyotype, including CNV and LOH evaluation, and multiplexed signal pathway profiling to individualize therapy in myelodysplastic syndrome (MDS)*

AWARDS AND RECOGNITIONS

November 2018 Borsa di perfezionamento SIES

November 2018 ASH Abstract Achievement Award

April 2018 Best abstract- EMN conference on Multiple Myeloma

December 2017 Research Fellowship Collegio Ghislieri- Annual Grant Recipient

December 2017 Young Investigator Programme 2018- Fondazione Veronesi- Annual Grant Recipient

November 2017 ASH Abstract Achievement Award

September 2017 Travel grant for the SOHO annual meeting, Houston, US

December 2016 Young Investigator Programme 2015- Fondazione Veronesi- Annual Grant Recipient

November 2016 Post-doc Programme Università Vita Salute San Raffaele, Annual Grant Recipient

October 2016 Borsa di perfezionamento SIES

June 2016 Travel grant for the SOHO annual meeting, Houston, US

May 2016 Borsa di studio residenziale- Fondazione MINTAS- Collegio Ghislieri - Pavia

February 2016 Premio Le Eccellenze Catanesi, Kiwanis

November 2015 Under 40 Hematology Contest 4 edition-finalist

November 2015 Premio Ercole Brusamolino 2015 Recipient, FIL (Fondazione Italiana Linfomi) for the best paper on Hodgkin's Lymphoma

October 2015 Travel Grant Recipient for EHA Hematology Tutorial on Anemia of Chronic Disease and Myelodysplastic Syndromes

June 2015 Travel Grant Recipient for EHA Annual Conference

June 2015 Selected as participant of EHA Master Class 2015-2016

April 2015 Annual Grant Recipient Fondazione Chianello, Palermo
May 2015 Borsa di studio residenziale- Fondazione MINTAS- Collegio Ghislieri - Pavia
November 2014 Young Investigator Programme 2015- Fondazione Veronesi- Annual Grant Recipient
November 2014 Under 40 Hematology Contest 3 edition-finalist
February 2014 AA&MDSIF Young Investigator Travel Support for AA&MDSIF 2014 Bone Marrow Failure Disease Scientific Symposium
December 2013 Celgene 2013 Future Leaders Award for Clinical Research in Hematology Recipient
November 2013 Under 40 Hematology Contest 2 edition-finalist
April 2013 Borsa di studio residenziale- Fondazione MINTAS- Collegio Ghislieri - Pavia
March 2013 Youngest Researcher 2013- Fondazione Veronesi
November 2012 Young Investigator Programme 2013- Fondazione Veronesi- Annual Grant Recipient
November 2012 Under 40 Hematology Contest 1 edition-finalist
October 2012 Travel Grant Recipient for XII SIES Conference
June 2012 Travel Grant Recipient for EHA Annual Conference
April 2012 Borsa di studio residenziale- Fondazione MINTAS- Collegio Ghislieri - Pavia
March 2012 AA&MDSIF Young Investigator Travel Support for AA&MDSIF 2012 Bone Marrow Failure Disease Scientific Symposium
June 2011 Travel Grant Recipient for EHA Annual Conference
October 2010 Travel Grant Recipient for XI SIES Conference
January 2010 PhD Scholarship at University of Catania- Scuola Superiore di Catania
May 2009 PREMIO DI LAUREA MASSIMINO
April 2004 Team leader in 8th Student ESA parabolic flight campaign (first 25 selected in Europe and Canada)
February 2002 Medaglia al merito del lavoro for outstanding high school career.
October 2001 University Scholarship at Scuola Superiore di Catania
October 2001 Alfiere del Lavoro Award- President of Italian Republic Prize to first 25 students selected in Italy for outstanding high school career.

SCIENTIFIC SOCIETY MEMBERSHIP

AACR, American Association for Cancer Research, since 2016, membership # 294326
EHA, European Haematology Association, since 2010, membership # 008089
ASH, American Society of Hematology, since 2013, membership # 1038879
SIE, Società Italiana di Ematologia, since 2017
SIES, Società Italiana di Ematologia Sperimentale, since 2010
SOHO, Society of Oncology and Hematology, since 2016

To date, I have published 64 articles in international refereed journals, gathering more than 600 citations, 15 Conference Proceedings, communicated 185 abstracts in around 30 national/international conferences/schools, presented more than 20 invited and contributed talks, communicated and shown more than 30 poster presentations in national and international meetings/workshops.
H index: 15, citations 905 (Source: Scopus, April, 2019).

PEER-REVIEWED PUBLICATIONS

1. Marangon M, Stefoni V, Castellino A, Visco C, Tani M, Cox MC, Marasca R, Tecchio C, Devizzi L, Monaco F, **Romano A**, Rusconi C, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL. **Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.** Clin Lymphoma Myeloma Leuk. 2019 Mar 29. pii: S2152-2650(19)30084-9. doi: 10.1016/j.clml.2019.03.020
2. Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, **Romano A**, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL. **Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.** Oncologist. 2019 Apr 2. pii: theoncologist.2018-0603. doi: 10.1634/theoncologist.2018-0603.
3. **Romano A**, Parrinello NL, Chiarenza A, Motta G, Tibullo D, Giallongo C, La Cava P, Camiolo G, Puglisi F, Palumbo GA, Di Raimondo F. **Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.** Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15801. PMID: 30768678.
4. Tirrò E., Massimino M., Romano C., Pennisi M.S., Stella S., Vitale S.R., Fidilio A., Manzella, Parrinello N.L., Stagno F., Palumbo G.A., La Cava P., **Romano A**, Di Raimondo F. and Vigneri P., **Chk1 Inhibition Restores Inotuzumab Ozogamicin Cytotoxicity in CD22-Positive Cells Expressing Mutant p53**, Front Oncol. 2019; 9: 57. PMCID: PMC6387953
5. Camiolo G, Tibullo D, Giallongo C, **Romano A**, Parrinello NL, Musumeci G, Di Rosa M, Vicario N, Brundo MV, Amenta F, Ferrante M, Copat C, Avola R, Li Volti G, Salvaggio A, Di Raimondo F, Palumbo GA. **α -Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload.** Int J Mol Sci. 2019 Jan 31;20(3). pii: E609. doi: 10.3390/ijms20030609. PubMed PMID: 30708965.
6. **Romano A**, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, Puglisi F, Parisi M, Piroso MC, Martino E, Conticello C, Palumbo GA, Di Raimondo F. **PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.** Expert Rev Mol Diagn. 2018 May 3:1-9.
7. Cerchione C, Nappi D, Pareto AE, **Romano A**, Martinelli V, Picardi M, Pane F, Catalano L. **Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience.** Anticancer Drugs. 2018 Apr;29(4):371-372.
8. Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A, Picardi M, **Romano A**, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravallotti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A. **Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.** J Clin Oncol. 2018 Jan 23;JCO2017752543. doi: 10.1200/JCO.2017.75.2543.
9. Giallongo C, Parrinello NL, La Cava P, Camiolo G, **Romano A**, Scalia M, Stagno F, Palumbo GA, Avola R, Li Volti G, Tibullo D, Di Raimondo F. **Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.** J Cell Mol Med. 2018 Feb;22(2):1070-1080.
10. **Romano A**, et al, **The neutrophil-lymphocyte ratio (NLR) and the lymphocyte-monocyte ratio (LMR) predict progression free survival in patients with newly diagnosed multiple myeloma treated upfront with novel agents**, accepted Blood Cancer Journal, 17-BCJ-0285R
11. Jurczak W, Ramanathan S, Giri P, **Romano A**, Mocikova H, Clancy J, Lechuga M, Casey M, Boni J, Giza A, Hess G. **Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.** Leuk. Lymphoma. 2017 Aug 3:1-9. doi: 10.1080/10428194.2017.1357175. PubMed PMID: 28768446.

12. Broccoli A, et al. **Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma.** *Haematologica*. 2017 Aug 3. pii: haematol.2017.171355. doi: 10.3324/haematol.2017.171355. PubMed PMID: 28775121.
13. Pellegrini C. et al. **Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma** *Oncotarget*. May 2017 (in press)
14. D'Urso D., Stefano A., **Romano A.**, Russo G., Cosentino S., Fallanca F., Gioè M., Attanasio M., Sabini M.G., Di Raimondo F. and Ippolito M. **Analysis of Metabolic Parameters Coming from Basal and Interim PET in Hodgkin Lymphoma** *Current Medical Imaging Reviews* March 2017 Vol 13 (in press)
15. **Romano A.**, Giallongo C., La Cava P, Parrinello N.L., Chiechi A., Vetro C., Tibullo D., Di Raimondo F., Liotta L, Espina V. and Palumbo G.A. **Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia** *Front. Pharm.* April 2017 (in press)
16. Conticello C, Parisi M, **Romano A.**, Calafiore V, Ancora F, La Fauci A, Consoli ML, Di Raimondo F. **Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.** *Future Oncol.* 2017 Feb;13(5s):3-6. doi: 10.2217/fon-2016-0368.
17. Ruggieri M, Praticò AD, Serra A, Maiolino L, Cocuzza S, Di Mauro P, Licciardello L, Milone P, Privitera G, Belfiore G, Di Pietro M, Di Raimondo F, **Romano A.**, Chiarenza A, Muglia M, Polizzi A, Evans DG. **Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.** *Acta Otorhinolaryngol Ital.* 2016 Oct;36(5):345-367. doi:10.14639/0392-100X-1093. PubMed PMID: 27958595; PubMed Central PMCID: PMC5225790
18. **Romano A.**, Consoli ML, Auteri G, Parisi M, Parrinello NL, Giallongo C, Tibullo D, Conticello C and Di Raimondo F. **R-ISS and NLR-ISS can Predict Time to Treatment in Smoldering Myeloma.** *J Clin Trials* 2016, 6:6 DOI: 10.4172/2167-0870.1000292
19. Tibullo D, Caporarello N, Giallongo C, Anfuso CD, Genovese C, Arlotta C, Puglisi F, Parrinello NL, Bramanti V, **Romano A.**, Lupo G, Toscano V, Avola R, Brundo MV, Di Raimondo F, Raccuia SA. **Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM).** *Nutrients.* 2016 Oct 1;8(10). pii: E611. PubMed PMID: 27706074.
20. Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, Sista MT, Fanti S, Biggi A, Vitolo U, Rigacci L, Merli F, Patti C, **Romano A.**, Levis A, Trentin L, Stelitano C, Borra A, Piccaluga PP, Hamilton-Dutoit S, Kamper P, Zaucha JM, Małkowski B, Kulikowski W, Tajer J, Subocz E, Rybka J, Steidl C, Broccoli A, Argnani L, Gascoyne RD, d'Amore F, Zinzani PL, Pileri SA. **The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.** *Lancet Haematol.* 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9. PubMed PMID: 27692305.
21. **Romano A.**, Laura Parrinello N, Vetro C, Tibullo D, Giallongo C, La Cava P, Chiarenza A, Motta G, Caruso AL, Villari L, Tripodo C, Cosentino S, Ippolito M, Consoli U, Gallamini A, Pileri S, Di Raimondo F. **The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin Lymphoma.** *Oncotarget.* 2016 Sep 14. doi: 10.18632/oncotarget.12024. PubMed PMID: 27637084.
22. Giallongo C*, **Romano A***, Parrinello NL, La Cava P, Brundo MV, Bramanti V, Stagno F, Vigneri P, Chiarenza A, Palumbo GA, Tibullo D, Di Raimondo F. **Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.** *PLoS One.* 2016 Jul 8;11(7):e0158392. doi: 10.1371/journal.pone.0158392. eCollection 2016.
23. **Romano A.**, Parrinello N.L. and Di Raimondo F. (2016) **Granulocytic Myeloid Derived Suppressor Cells are Increased in Multiple Myeloma and can Predict outcome in Patients Treated upfront with Lenalidomide.** *Ann. Hematol. Oncol.* 3 (2): 1078-1085.
24. La Nasa G, Greco M, Littera R, Oppi S, Celeghini I, Caria R, Lai S, Porcella R, Martino M, **Romano A.**, Di Raimondo F, Gallamini A, Carcassi C, Caocci G. **The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic**

- Hodgkin lymphoma.** J Hematol Oncol. 2016 Mar 16;9(1):26.
25. Giallongo C, Tibullo D, Parrinello NL, La Cava P, Di Rosa M, Bramanti V, Di Raimondo C, Conticello C, Chiarenza A, Palumbo GA, Avola R, **Romano A**, Di Raimondo F. **Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC).** Oncotarget. 2016 Mar 7. doi: 10.18632/oncotarget.7969. PubMed PMID: 26967390.
 26. Tibullo D, Barbagallo I, Giallongo C, Vanella L, Conticello C, **Romano A**, Saccone S, Godos J, Di Raimondo F, Li Volti G. **Heme Oxygenase-1 Nuclear Translocation Regulates Bortezomib-Induced Cytotoxicity and Mediates Genomic Instability in Myeloma Cells.** Oncotarget. 2016 Feb 22. doi: 10.18632/oncotarget.7563.
 27. Magliano A., Camarda M., Lombardo S.F., Di Martino R., Cascio M., **Romano A**, Minafra L., Russo G., Gilardi M., Di Raimondo F., Scalese S., La Magna A. **Elution time changes due to anomalous DEP effects in microchannels under uniform and non-uniform electric fields**, Sensing and Bio-Sensing Research, Available online 17 February 2016, ISSN 2214-1804
 28. Di Martino R, Camarda M, Cascio M, Gallo M, Magliano A, Baldo S, **Romano A**, Minafra L, Forte G I, Russo G, Gilardi M C, Di Raimondo F, Scalese S and La Magna A, **Analysis of the role of elution buffers on the separation capabilities of dielectrophoretic devices**, Sensing and Bio-Sensing Research, Available online 8 December 2015, ISSN 2214-1804
 29. S. Baldo, S. Buccheri, A. Ballo, M. Camarda, A. La Magna, M.E. Castagna, **A. Romano**, D. Iannazzo, F. Di Raimondo, G. Neri, S. Scalese, **Carbon nanotube-based sensing devices for human arginase-1 detection**, (2015), doi:10.1016/j.sbsr.2015.11.011
 30. **Romano A**, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, Di Raimondo F, Borrello I. **Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.** Ann Hematol. 2015 Nov;94(11):1875-83.
 31. Vetro C, Bonanno G, Giulietti G, **Romano A**, Conticello C, Chiarenza A, Spina P, Coppolino F, Cunsolo R, Raimondo FD. **Rare gastrointestinal lymphomas: The endoscopic investigation.** World J Gastrointest Endosc. 2015 Aug 10;7(10):928-49.
 32. Vetro C, Rosso R, Palmucci S, Russello M, Colletta G, Romeo MA, Ximenes B, **Romano A**, Palumbo GA, Di Raimondo F. **Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome.** J Clin Apher. 2015 Sep 28. doi: 10.1002/jca.21434
 33. Tibullo D, Di Rosa M, Giallongo C, La Cava P, Parrinello NL, **Romano A**, Conticello C, Brundo MV, Saccone S, Malaguarnera L, Di Raimondo F. **Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells.** Front Pharmacol. 2015 Oct 14;6:226. doi: 10.3389/fphar.2015.00226.
 34. Vetro C, **Romano A**, Ancora F, Coppolino F, Brundo MV, Raccuia SA, Puglisi F, Tibullo D, La Cava P, Giallongo C, Parrinello NL. **Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells.** Front Oncol. 2015 May 21;5:104
 35. Milone G, Camuglia MG, Avola G, Di Marco A, Leotta S, Cupri A, Spina P, **Romano A**, Spina E, Azzaro MP, Berritta D, Parisi M, Tripepi G. **Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment.** Exp Hematol. 2015 Feb 20. pii: S0301-472X(15)00042-9. doi: 10.1016/j.exphem.2015.02.002.
 36. Parrinello N, Di Raimondo F, **Romano A**. **Myeloid Derived Suppressor Cells in Multiple Myeloma.** Exp Rev Immunol Vaccine Information 2014; 1: 14-20.
 37. Vetro C, **Romano A**, Amico I, Conticello C, Motta G, Figuera A, Chiarenza A, Di Raimondo C, Giulietti G, Bonanno G, Palumbo GA, Di Raimondo F. **Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up.** World J Gastroenterol. 2014 Sep 28;20(36):12993-3005
 38. **Romano A**, Marescalco MS, Liardo C, Villari L, Vetro C, Conticello C, Di Raimondo F, Ferlito S. **Oral lesion as unusual first manifestation of multiple myeloma: case reports and review of the literature.** Case Rep Hematol.2014;2014:529452.
 39. **Romano A**, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, Motta G, Palumbo GA, Ippolito M, Consoli U, Raimondo FD. **Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.** Br J Haematol. 2014 Nov 7. doi: 10.1111/bjh.13198. [Epub ahead of print] PubMed PMID: 25376846.

40. Giallongo C, Parrinello N, Tibullo D, La Cava P, **Romano A**, Chiarenza A, Barbagallo I, Palumbo GA, Stagno F, Vigneri P, Di Raimondo F. **Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients.** PLoS One. 2014 Jul 11;9(7):e101848. doi: 10.1371/journal.pone.0101848. eCollection 2014. PubMed PMID: 25014230.
41. **Romano A**, Conticello C, Cavalli M, Vetro C, La Fauci A, Parrinello NL, Di Raimondo F. **Immunological Dysregulation in Multiple Myeloma Microenvironment.** Biomed Res Int. 2014;2014:198539. Epub 2014 Jun 11. Review. PubMed PMID: 25013764; PubMed Central PMCID: PMC4071780.
42. **Romano A**, Conticello C, Cavalli M, Vetro C, Di Raimondo C, Di Martina V, Schinocca E, La Fauci A, Parrinello NL, Chiarenza A, Di Raimondo F. **Salvage Therapy of Multiple Myeloma: The New Generation Drugs.** Biomed Res Int.2014;2014:456037. Epub 2014 May 19. Review. PubMed PMID: 24967371; PubMed Central PMCID: PMC4055245.
43. **Romano A**, Vetro C, Caocci G, Greco M, Parrinello NL, Di Raimondo F, La Nasa G. **Immunological deregulation in classic hodgkin lymphoma.** Mediterr J Hematol Infect Dis. 2014 Jun 1;6(1):e2014039. doi: 10.4084/MJHID.2014.039. eCollection 2014. Review. PubMed PMID: 24959336; PubMed Central PMCID: PMC4063611.
44. **Romano A**, Chiarenza A, Conticello C, Cavalli M, Vetro C, Di Raimondo C, Cunsolo R, Palumbo GA, Di Raimondo F. **Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.** Eur J Haematol. 2014 Mar 27. doi: 10.1111/ejh.12325.
45. Gambella M, Rocci A, Passera R, Gay F, Omedè P, Crippa C, Corradini P., **Romano A**, Rossi D. et al. **High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.** Haematologica. 2014;99(2):e14-e6.
46. Vetro C, Chiarenza A, **Romano A**, Amico I, Calafiore V, Di Raimondo C, Coppolino F, Di Raimondo F. **Prognostic Assessment and Treatment of Primary Gastric Lymphomas: How Endoscopic Ultrasonography Can Help in Tailoring Patient Management.** Clin Lymphoma Myeloma Leuk. 2013 Nov 15. PubMed PMID: 24369919.
47. Vetro C, Giulietti G, Calafiore V, **Romano A**, Di Raimondo F. **A snapshot of asparaginase-induced liver insufficiency.** Eur J Haematol. 2013 Dec 14. PubMed PMID: 24329712.
48. Conticello C., Vetro C., **Romano A**., Amato G. Schinocca L., Cosentino S., Ippolito M., Giustolisi R., Di Raimondo F., **Abnormal F-18 fluorodeoxyglucose uptake of the lung in immunocompromised lymphoma patients in complete remission: report of two cases and revision of literature,** European Journal of Inflammation, 2013, Vol. 11, no. 3, 893-899
49. Conticello C, Giuffrida R, Parrinello N, Buccheri S, Adamo L, Sciuto MR, Colarossi C, Aiello E, Chiarenza A, **Romano A**, Salomone E, Gulisano M, Giustolisi R, Di Raimondo F. **CD200 expression in patients with Multiple Myeloma: Another piece of the puzzle.** Leuk Res. 2013 Sep 23. doi:pii: S0145-2126(13)00287-7. 10.1016/j.leukres.2013.08.006. PubMed PMID: 24183830.
50. Gallamini A, Di Raimondo F, La Nasa G, **Romano A**, Borra A, Greco M. **Standard therapies versus novel therapies in Hodgkin lymphoma.** Immunol Lett. 2013 Oct 16. doi:pii: S0165-2478(13)00134-X. 10.1016/j.imlet.2013.09.011. PubMed PMID: 24140162.
51. Savage SA, Pulsipher MA, **Romano A**, Berlyne D. **Aplastic Anemia & MDS International Foundation (AA&MDSIF): bone marrow failure disease scientific symposium 2012.** Leuk Res. 2013 Jul;37(7):848-51. doi:10.1016/j.leukres.2013.04.013.
52. **Romano A**, Conticello C, Di Raimondo F. **Bortezomib for the treatment of previously untreated multiple myeloma.** Immunotherapy 5(4), 327–352 (2013).
53. **Romano A**, Uccello G., Spina P., Cunsolo R., Vetro C. and Di Raimondo F. **Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients** *Current Cancer Therapy Reviews, Volume 9, Number 1, February 2013 , pp. 1-7(7)*
54. Giuffrida G., Cingari R., Parrinello N., **Romano A**., Triolo A., Franceschino M. and Di Raimondo F. **Bone turnover markers in patients with type 1 Gaucher disease** *Hematology Reports* 2012; volume 4: e21- DOI: 10.4081/hr.2012.e21
55. **Romano A.**, A. Chiarenza, U. Consoli, C. Conticello, S. Forte, G. Uccello, C. Vetro, M. Cavalli, F.

- Coppolino, G. A. Palumbo, and F. Di Raimondo **Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma** *Ann Oncol*_2012 doi:10.1093/annonc/mds531 PMID: 23136226
56. Chiechi A, Mueller C, Boehm KM, **Romano A**, Benassi MS, Picci P, Liotta LA, Espina V **Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples.** *Biotechniques* 2012 Sep;0(0):1-7 PMID: 22946677
 57. **Romano A**, Vetro C, Donnarumma D, Forte S, Ippolito M and Di Raimondo F. **Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma.** *Haematologica* 2012;97(6):e21-23.doi:10.3324/haematol.2012.064576
 58. Vetro C., **Romano A**, Chiarenza A., Conticello C., Donnarumma D., Gorgone A, Coppolino F., Palumbo G.A., Bonanno G. and Di Raimondo F. **Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up.** *Hematol. Oncol.* 2011 Dec 20. doi: 10.1002/hon.1022.
 59. **Romano A**, Vetro C, Adriani M. **Advances in understanding regulatory myeloid cells.** *Cancer Biol Ther.* 2011 Jun 1;11(11). PubMed PMID: 21474999.
 60. Conticello C, Giuffrida R, Adamo L, Anastasi G, Martinetti D, Salomone E, Colarossi C, Amato G, Gorgone A, **Romano A et al: NF-kappa B localization in multiple myeloma plasma cells and mesenchymal cells.** *Leukemia Research* 2011, **35**(1):52-60.
 61. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, **Romano A**, Liberati AM, Siniscalchi A, Petrucci MT, Nozzoli C, Patriarca F, Offidani M, Ria R, Omedè P, Bruno B, Passera R, Musto P, Boccadoro M, Sonneveld P, Palumbo A. **Complete response correlates with long-term progression-free and overall survivals in elderly myeloma treated with novel agents: analysis of 1175 patients.** *Blood* 2011
 62. Giallongo C, La Cava P, Tibullo D, Parrinello N, Barbagallo I, Del Fabro V, Stagno F, Conticello C, **Romano A**, Chiarenza A, Palumbo GA, Di Raimondo F. **Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of Chronic Myeloid Leukemia cells.** *Eur J Haematol* 2011
 63. Palumbo A, Cavo M, Bringhen S, Zamagni E, **Romano A**, et. al. **Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide:A Phase III, Open-Label, Randomized Trial.** *J Clin Oncol.* 2011 Jan 31. PubMed PMID: 21282540.
 64. Barresi V, Palumbo GA, Musso N, Consoli C, Capizzi C, Meli CR, **Romano A**, Di Raimondo F, Condorelli DF: **Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML.** *Leukemia Research* 2010, **34**(11):1539-1542.
 65. Barresi V, **Romano A**, Musso N, Capizzi C, Consoli C, Martelli MP, Palumbo G, Di Raimondo F, Condorelli DF: **Broad Copy Neutral-Loss of Heterozygosity Regions and Rare Recurring Copy Number Abnormalities in Normal Karyotype-Acute Myeloid Leukemia Genomes.** *Genes Chromosomes & Cancer* 2010, **49**(11):1014-1023.

BOOK CHAPTERS

1. **A. Romano**, V. Barresi, C. Consoli, N. Musso, C. Capizzi, G. A. Palumbo, F. Di Raimondo and D. F. Condorelli, **Conventional and molecular cytogenetic techniques and their application in Myelodysplastic Syndromes**, in *Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy*- Chapter 6, NOVA Publishers, ISBN 978-1-62417-580-0, edited by Hamid Sayar (Indiana University Simon Cancer Center, Indianapolis, IN, USA)
2. **Romano A.**, **Gammopatie monoclonali**, in Bosi A., De Stefano V., Di Raimondo F., La Nasa G *MANUALE DI MALATTIE DEL SANGUE*, 2012, Elsevier, ISBN: 9788821432620.
3. Vetro C., **Romano A.**, Palumbo G.A., Bonanno G. and Di Raimondo F. **Role of the Endoscopic Ultrasonography in the Management of Gastric Lymphomas: Our Experience and Review of Literature** in: *Ultrasound Imaging - Medical Applications* ISBN 978-953-307-279-1, Edited by: Igor V. Minin and Oleg V. Minin, InTech (2011)

4. Di Raimondo F, **Romano A**, ***Sangue***, in Tamburino - Castellino - Di Maria - Di Raimondo - Ettore - Fiore – Purrello, Il Rasario- Manuale di Semeiotica Medica, 2010, Idelson – Gnocchi ISBN: 8879475274
5. Di Raimondo F, **Romano A**, Schinocca L Chiarenza A, ***Rischio di infertilità nella terapia medica dei tumori ematologici***, in Banna G. L., Catalano F., Condorelli R., Peccatori F., Preservazione della fertilità in oncologia, 2009, Laurencin editor, www.medinews.it/bin.